Press Releases

PROSPER, Texas--(BUSINESS WIRE)-- MySpaLive, a leading cosmetic training and software company, is reaffirming its dedication to providing comprehensive and safe training for individuals performing cosmetic injections, including neurotoxins, fillers, IV therapy, and weight loss treatments.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240606722832/en/

Neurotoxin training on model (Photo: Business... (continue reading...)

AUSTIN, Texas--(BUSINESS WIRE)-- CrowdStrike (Nasdaq: CRWD) today announced that it has been named a Leader in The Forrester Wave™: Cybersecurity Incident Response Services, Q2 2024. “A product powerhouse in detection and response tech, CrowdStrike’s unwavering mission and vision are to stop breaches,” said the report.

The powerful combination of the industry-leading CrowdStrike Falcon® cybersecurity platform and its elite services team deliver the speed and... (continue reading...)

LONDON, Ontario, June 10, 2024 (GLOBE NEWSWIRE) -- London Research & Pharmaceuticals presented notable pre-clinical data about its lead compound, LRP-661, also known as Cannabidiol Sulphate (CBDS), at the Seventeenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XVII) conference in Madrid, Spain, May 5th to May 8th, 2024.

LRP-661’s data highlights its superior safety, efficacy, bioavailability, and PK in multiple species. Furthermore, LRP-661’s oral... (continue reading...)

LONDON, Ontario, June 10, 2024 (GLOBE NEWSWIRE) -- London Research & Pharmaceuticals presented notable pre-clinical data about its lead compound, LRP-661, also known as Cannabidiol Sulphate (CBDS), at the Seventeenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XVII) conference in Madrid, Spain, May 5th to May 8th, 2024.

LRP-661’s data highlights its superior safety, efficacy, bioavailability, and PK in multiple species. Furthermore, LRP-661’s oral... (continue reading...)

• Double-blind, placebo-controlled study aims to measure safety and efficacy of INDV-2000 over 3 months in participants with moderate to severe Opioid Use Disorder.
• INDV-2000 is an investigational non-opioid treatment that acts through the orexin pathway, shown to play a key role in the neurobiology of substance use disorder in animals.
• Recent animal studies have demonstrated that selective Orexin-1 receptor antagonism can reduce self-administration of opioids and... (continue reading...)